Mp05-15 Identification of Tumor Antigens and Immune Subtypes of Prostate Adenocarcinoma for Mrna Vaccine Development

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I (MP05)1 May 2024MP05-15 IDENTIFICATION OF TUMOR ANTIGENS AND IMMUNE SUBTYPES OF PROSTATE ADENOCARCINOMA FOR MRNA VACCINE DEVELOPMENT Naijin Xu, Li Xu, and Gonghui Li Naijin XuNaijin Xu , Li XuLi Xu , and Gonghui LiGonghui Li View All Author Informationhttps://doi.org/10.1097/01.JU.0001008740.27639.cc.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The mRNA-based cancer vaccines have been viewed as promising strategies and the next hotspots in cancer immunotherapy. However, the effectiveness of this treatment on prostate adenocarcinoma (PRAD) has yet to be well demonstrated. The objective of this study was to investigate the relationship between pyroptosis phenotypes and the tumor immune microenvironment in PRAD for the development of mRNA vaccines and the selection of suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 554 PRAD patients were extracted from The Cancer Genome Atlas (TCGA)and MSKCC databases. GEPIA was used to calculate differential expression levels and prognostic indices, the cBioPortal program was used to compare genetic alterations, and TIMER was used to explore the correlation between genes and immune infiltrating cells. A consensus cluster was used for consistency matrix construction and data clustering, DDRtree was used for functional annotation, and graph learning-based dimensional reduction was used to depict the immune landscape. RESULTS: We identified 107 frequently mutated and upregulated cancer-related genes associated with poor prognosis and infiltration of antigen-presenting cells (APCs) in PRAD. Moreover, we discovered distinct pyroptosis subtypes (PS1 and PS2) that reflect the tumor immune microenvironment and can predict patient prognosis. PS1 exhibited immune-activated phenotypes and correlated to better survival compared to the PS2 subtypes. PS2 tumors were immunologically cold and associated with a higher tumor mutation burden. Key genes, including CITED2, DNMT1, HDAC6, KIF23, and mettl14, were found to correlate with the immune response and pyroptosis in PRAD. CONCLUSIONS: CITED2, DNMT1, HDAC6, KIF23, and METTL14 serve as promising antigens for developing anti-PRAD mRNA vaccines. Our research strategies contribute to enhancing our understanding of tumor immune microenvironment infiltration characteristics, guiding more effective immunotherapy strategies, and selecting appropriate patients for tumor vaccine therapy. Source of Funding: This work was supported by the National Natural Science Foundation of China (No.82103619) and the Medical and Health Science and Technology Plan of Zhejiang Province (No. 2022RC194) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e48 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Naijin Xu More articles by this author Li Xu More articles by this author Gonghui Li More articles by this author Expand All Advertisement PDF downloadLoading ...